These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27004155)

  • 1. KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.
    Loaiza-Bonilla A; Jensen CE; Shroff S; Furth E; Bonilla-Reyes PA; Deik AF; Morrissette J
    Cureus; 2016 Feb; 8(2):e478. PubMed ID: 27004155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
    Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
    Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.
    Korphaisarn K; Loree JM; Nguyen V; Coulson R; Holla V; Litzenburger BC; Chen K; Mills GB; Maru DM; Meric-Bernstan F; Shaw KRM; Kopetz S
    Oncotarget; 2017 Aug; 8(34):57882-57888. PubMed ID: 28915719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
    Loaiza-Bonilla A; Clayton E; Furth E; O'Hara M; Morrissette J
    Ecancermedicalscience; 2014; 8():479. PubMed ID: 25435907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
    Subbiah V; Khawaja MR; Hong DS; Amini B; Yungfang J; Liu H; Johnson A; Schrock AB; Ali SM; Sun JX; Fabrizio D; Piha-Paul S; Fu S; Tsimberidou AM; Naing A; Janku F; Karp DD; Overman M; Eng C; Kopetz S; Meric-Bernstam F; Falchook GS
    JCI Insight; 2017 Apr; 2(8):. PubMed ID: 28422758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment.
    Lee MS; Cho HJ; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Cho YB; Kim ST
    Ther Adv Med Oncol; 2020; 12():1758835920965842. PubMed ID: 33224274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Yoon SE; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
    J Cancer; 2019; 10(7):1611-1615. PubMed ID: 31205516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report.
    Baik H; Lee HJ; Park J; Park HY; Park J; Lee S; Bae KB
    Mol Clin Oncol; 2021 Nov; 15(5):243. PubMed ID: 34650810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral sensorineural hearing loss induced by regorafenib.
    Cheng J; Wang L; Zhu LN; Wang L
    J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer.
    Wang F; Liu G
    Int J Gen Med; 2022; 15():5651-5659. PubMed ID: 35734201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.
    Garde Noguera J; Jantus-Lewintre E; Gil-Raga M; Evgenyeva E; Maciá Escalante S; Llombart-Cussac A; Camps Herrero C
    Mol Clin Oncol; 2017 Mar; 6(3):403-408. PubMed ID: 28451421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical appraisal of the use of regorafenib in the management of colorectal cancer.
    Festino L; Fabozzi A; Manzo A; Gambardella V; Martinelli E; Troiani T; De Vita F; Orditura M; Ciardiello F; Morgillo F
    Cancer Manag Res; 2013; 5():49-55. PubMed ID: 23610528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations.
    Zhang H; Bai H; Yang X; Zhong J; An T; Zhao J; Wang J
    Thorac Cancer; 2016 Jan; 7(1):24-31. PubMed ID: 26813477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.